Recent‐onset schizophrenia (ROS) represents a critical period that can greatly influence the clinical course of schizophrenia. The use of long‐acting injectable antipsychotics (LAIs) in this period is increasingly being considered as a first‐line treatment option. Aripiprazole LAI (ALAI) is the newest of all LAI's available on the market, with limited data on its effects on hospitalization rates after first episode of schizophrenia. It was our goal to evaluate whether ALAI has an effect on hospitalization rates, number of bed days and clinical improvement in patients with ROS.

中文翻译：

---

阿立哌唑长效注射用抗精神病药对新发精神分裂症住院治疗的影响

新发精神分裂症（ROS）代表了一个关键时期，可以极大地影响精神分裂症的临床病程。在此期间使用长效注射用抗精神病药物 (LAIs) 越来越多地被视为一线治疗选择。阿立哌唑 LAI (ALAI) 是市场上所有 LAI 中最新的一种，关于其对精神分裂症首发后住院率影响的数据有限。我们的目标是评估 ALAI 是否对 ROS 患者的住院率、卧床天数和临床改善有影响。